Literature DB >> 24040792

Effects of brain IKKβ gene silencing by small interfering RNA on P-glycoprotein expression and brain damage in the rat kainic acid-induced seizure model.

Nian Yu, Hao Liu, Yan-Fang Zhang, Ling-Ying Su, Xin-Hong Liu, Le-Chao Li, Jin-Bo Hao, Xian-Jing Huang, Qing Di1.   

Abstract

Multidrug resistance mediated by over-expression of P-glycoprotein (P-gp) in brain is an important mechanism accounting for the drug-therapy failure in epilepsy. Over-expression of P-gp in epilepsy rat brain may be regulated by inflammation and nuclear factor-kappa B (NF-κB) activation. Inhibitory κ B kinase subunit β (IKKβ) is an up-stream molecular controlling NF-κB activation. With the small interfering RNA (siRNA) technique and kainic acid (KA)-induced rat epileptic seizure model, the present study was aimed to further evaluate the role of NF-κB inhibition, via blocking IKKβ gene transcription, in the epileptic brain P-gp over-expression, seizure susceptibility, and post-seizure brain damage. siRNA targeting IKKβ was administered to rats via intracerebroventricular injection before seizure induction by KA microinjection; scrambled siRNA was used as control. Brain mRNA and protein levels of IKKβ and P-gp were detected by RT-PCR and immunohistochemistry. NF-κB activity was measured by electrophoretic mobility shift assay. Latency to grade III or V seizure onset was recorded, brain damage was evaluated by neuronal cell counting and epileptiform activity was monitored by electroencephalography. IKKβ siRNA pre-treatment inhibited NF-κB activation and abolished P-gp over-expression in KA-induced epileptic rat brain, accompanied by decreased seizure susceptibility. These findings suggested that epileptogenic-induced P-gp over-expression could be regulated by IKKβ through the NF-κB pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24040792     DOI: 10.2174/18715273113129990106

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  7 in total

1.  Pregnane X Receptor Not Nuclear Factor-kappa B Up-regulates P-glycoprotein Expression in the Brain of Chronic Epileptic Rats Induced by Kainic Acid.

Authors:  Nian Yu; Yan-Fang Zhang; Kang Zhang; Yong-Fei Cheng; Hai-Yan Ma; Qing Di
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

2.  The Prevention and Reversal of a Phenytoin-Resistant Model by N-acetylcysteine Therapy Involves the Nrf2/P-Glycoprotein Pathway at the Blood-Brain Barrier.

Authors:  Qiankun Liu; You Wang; Dandan Tan; Yong Liu; Peng Zhang; Limin Ma; Minxue Liang; Yangmei Chen
Journal:  J Mol Neurosci       Date:  2022-08-26       Impact factor: 2.866

3.  Enhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrier.

Authors:  Jian-Sheng Liu; Jian-Hong Wang; Jie Zhou; Xing-Hua Tang; Lan Xu; Teng Shen; Xun-Yi Wu; Zhen Hong
Journal:  Int J Nanomedicine       Date:  2014-08-16

4.  HMGB1 Contributes to the Expression of P-Glycoprotein in Mouse Epileptic Brain through Toll-Like Receptor 4 and Receptor for Advanced Glycation End Products.

Authors:  Yan Chen; Xian-Jing Huang; Nian Yu; Yuan Xie; Kang Zhang; Fang Wen; Hao Liu; Qing Di
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

5.  HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-κB signaling pathway.

Authors:  Yuan Xie; Nian Yu; Yan Chen; Kang Zhang; Hai-Yan Ma; Qing Di
Journal:  Mol Med Rep       Date:  2017-06-14       Impact factor: 2.952

6.  M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects.

Authors:  Hong Xiao; Yu Guo; Bo Li; Xiaoxia Li; Yong Wang; Shisong Han; Du Cheng; Xintao Shuai
Journal:  ACS Cent Sci       Date:  2020-07-01       Impact factor: 14.553

Review 7.  How to Find Candidate Drug-targets for Antiepileptogenic Therapy?

Authors:  Nian Yu; Xing-Jian Lin; Qing Di
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.